FERGI Trial – Commentary by DR. Sunil Verma

The FERGI phase II study of the PI3K inhibitor pictilisib (GDC-0941) plus fulvestrant vs fulvestrant plus placebo in patients with ER+, aromatase inhibitor (AI)-resistant advanced or metastatic breast cancer Part I results, presented by Dr. Verma